ADAR1-dependent editing regulates human β cell transcriptome diversity during inflammation.
RNA editing
T1D (type 1 diabetes)
beta cell (β cell)
inflammation
transcriptome
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
09
2022
accepted:
01
11
2022
entrez:
15
12
2022
pubmed:
16
12
2022
medline:
17
12
2022
Statut:
epublish
Résumé
Enterovirus infection has long been suspected as a possible trigger for type 1 diabetes. Upon infection, viral double-stranded RNA (dsRNA) is recognized by membrane and cytosolic sensors that orchestrate type I interferon signaling and the recruitment of innate immune cells to the pancreatic islets. In this context, adenosine deaminase acting on RNA 1 (ADAR1) editing plays an important role in dampening the immune response by inducing adenosine mispairing, destabilizing the RNA duplexes and thus preventing excessive immune activation. Using high-throughput RNA sequencing data from human islets and EndoC-βH1 cells exposed to IFNα or IFNγ/IL1β, we evaluated the role of ADAR1 in human pancreatic β cells and determined the impact of the type 1 diabetes pathophysiological environment on ADAR1-dependent RNA editing. We show that both IFNα and IFNγ/IL1β stimulation promote ADAR1 expression and increase the A-to-I RNA editing of Alu-Containing mRNAs in EndoC-βH1 cells as well as in primary human islets. We demonstrate that ADAR1 overexpression inhibits type I interferon response signaling, while ADAR1 silencing potentiates IFNα effects. In addition, ADAR1 overexpression triggers the generation of alternatively spliced mRNAs, highlighting a novel role for ADAR1 as a regulator of the β cell transcriptome under inflammatory conditions.
Identifiants
pubmed: 36518246
doi: 10.3389/fendo.2022.1058345
pmc: PMC9742459
doi:
Substances chimiques
Adenosine Deaminase
EC 3.5.4.4
Interferon Type I
0
RNA, Double-Stranded
0
RNA, Messenger
0
RNA-Binding Proteins
0
ADAR protein, human
EC 3.5.4.37
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1058345Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK127786
Pays : United States
Informations de copyright
Copyright © 2022 Szymczak, Cohen-Fultheim, Thomaidou, de Brachène, Castela, Colli, Marchetti, Levanon, Eizirik and Zaldumbide.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Genet. 2012 Nov;44(11):1243-8
pubmed: 23001123
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Biol Chem. 2017 Feb 24;292(8):3466-3480
pubmed: 28077579
Mol Ther. 2004 Feb;9(2):209-17
pubmed: 14759805
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Cell Metab. 2018 Dec 4;28(6):946-960.e6
pubmed: 30078552
Front Immunol. 2019 Jul 25;10:1763
pubmed: 31404141
Nat Commun. 2020 Feb 7;11(1):799
pubmed: 32034135
Nat Genet. 2019 Nov;51(11):1588-1595
pubmed: 31676868
Cell Death Dis. 2019 Dec 4;10(12):913
pubmed: 31801951
J Biol Chem. 2022 Sep;298(9):102267
pubmed: 35850307
EBioMedicine. 2018 Oct;36:367-375
pubmed: 30269996
Front Endocrinol (Lausanne). 2020 Sep 15;11:568446
pubmed: 33042023
Biomedicines. 2021 Feb 17;9(2):
pubmed: 33671312
F1000Res. 2015 Oct 14;4:1070
pubmed: 26674615
Front Oncol. 2020 Dec 10;10:593989
pubmed: 33363023
Trends Microbiol. 2019 Jan;27(1):75-85
pubmed: 30201512
Bioessays. 2017 Nov;39(11):
pubmed: 28960389
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
J Clin Invest. 2011 Sep;121(9):3589-97
pubmed: 21865645
Diabetologia. 2020 Oct;63(10):1999-2006
pubmed: 32894310
Nat Methods. 2019 Nov;16(11):1131-1138
pubmed: 31636457
Front Immunol. 2021 Apr 19;12:667989
pubmed: 33953728
Tumour Biol. 2017 Oct;39(10):1010428317734816
pubmed: 29022489
Microorganisms. 2020 Sep 15;8(9):
pubmed: 32942706
Cell Rep. 2018 Apr 3;23(1):50-57
pubmed: 29617672
Nat Commun. 2014 Aug 27;5:4726
pubmed: 25158696
Front Endocrinol (Lausanne). 2022 Sep 12;13:991632
pubmed: 36171907
Nat Rev Mol Cell Biol. 2016 Feb;17(2):83-96
pubmed: 26648264
Nat Rev Endocrinol. 2021 Mar;17(3):150-161
pubmed: 33293704
Nat Commun. 2020 May 22;11(1):2584
pubmed: 32444635
Mol Cell Biol. 2005 Aug;25(16):6956-63
pubmed: 16055709
Genome Res. 2014 Mar;24(3):365-76
pubmed: 24347612
J Exp Med. 1997 Feb 3;185(3):531-9
pubmed: 9053453
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Sci Adv. 2021 Jan 6;7(2):
pubmed: 33523973
J Mol Med (Berl). 2016 Oct;94(10):1095-1102
pubmed: 27044320
Nat Rev Endocrinol. 2020 Jul;16(7):349-362
pubmed: 32398822
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
J Autoimmun. 2018 Nov;94:7-15
pubmed: 30115527
Cell Stem Cell. 2020 Aug 6;27(2):300-314.e11
pubmed: 32396862
J Transl Med. 2019 Sep 23;17(1):319
pubmed: 31547885